Cargando…
Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?
SIMPLE SUMMARY: Cell surface proteases (so-called ectoproteases) are associated with cancer, and their targeting may confer valuable options for the improvement of cancer treatment outcome. Over the past 20 years, the permanent development of a multitude of inhibitors against several ectoproteases (...
Autores principales: | Verhulst, Emile, Garnier, Delphine, De Meester, Ingrid, Bauvois, Brigitte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833564/ https://www.ncbi.nlm.nih.gov/pubmed/35158891 http://dx.doi.org/10.3390/cancers14030624 |
Ejemplares similares
-
Maternal sleep position: what do we know where do we go?
por: O’Brien, Louise M, et al.
Publicado: (2015) -
Coffee and digestive cancers—what do we know, and where do we go?
por: Loftfield, Erikka, et al.
Publicado: (2020) -
Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
por: Aprotosoaie, Ana Clara, et al.
Publicado: (2022) -
Resistance in tuberculosis: what do we know and where can we go?
por: Green, Keith D., et al.
Publicado: (2013) -
The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?
por: Agarwal, Rajiv, et al.
Publicado: (2011)